The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Phase I Results for Enasidenib in AML

Eytan M. Stein, MD
Published Online: 1:29 AM, Wed June 7, 2017

Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I dose escalation and expansion study of enasidenib in mutant IDH-2 relapsed or refractory acute myeloid leukemia (AML) during the 2017 ASCO Annual Meeting.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.